Summary of Juno Therapeutics, Inc. (NASDAQ:JUNO) Ratings

May 3, 2018 - By Ira Colvard

Juno Therapeutics, Inc. (NASDAQ:JUNO) Corporate Logo
During 2017 Q4 the big money sentiment increased to 1.67. That’s change of 0.23, from 2017Q3’s 1.44. 25 investors sold all, 47 reduced holdings as Juno Therapeutics, Inc. ratio is positive. 75 increased positions while 45 funds amassed positions. Funds hold 68.38 million shares thus 3.41% more from 2017Q3’s 66.13 million shares.
Missouri-based Stifel Fincl has invested 0% in Juno Therapeutics, Inc. (NASDAQ:JUNO). State Of Alaska Department Of Revenue invested 0% of its capital in Juno Therapeutics, Inc. (NASDAQ:JUNO). 57,209 are held by Pub Employees Retirement System Of Ohio. Brown Advisory, a Maryland-based fund reported 250,487 shs. Moreover, Peak6 Invs L P has 0% invested in Juno Therapeutics, Inc. (NASDAQ:JUNO). Wellington Shields Co Ltd Llc owns 0.15% invested in Juno Therapeutics, Inc. (NASDAQ:JUNO) for 6,200 shs. Mitsubishi Ufj Tru & Banking owns 879,560 shs. Bancorporation Of Montreal Can, Ontario – Canada-based fund reported 7,107 shs. Susquehanna Grp Llp invested in 352,027 shs or 0.01% of the stock. Jane Street Gp Llc reported 0% of its capital in Juno Therapeutics, Inc. (NASDAQ:JUNO). Barclays Public Limited owns 124,704 shs. Jpmorgan Chase And reported 70,286 shs or 0% of all its holdings. Gideon Capital Advsr Inc, a New York-based fund reported 4,716 shs. Cambridge Invest Advsrs Incorporated has 4,564 shs for 0% of their capital. Rock Springs Cap Management Limited Partnership has invested 0.48% of its capital in Juno Therapeutics, Inc. (NASDAQ:JUNO).

Juno Therapeutics, Inc. (NASDAQ:JUNO) Ratings Coverage

A total of 12 analysts rate Juno Therapeutics (NASDAQ:JUNO) as follows: 0 “Buy”, 12 “Hold” and 0 “Sell”. Тherefore 0 are bullish. (NASDAQ:JUNO) has 14 ratings reports on May 3, 2018 according to StockzIntelligence. On Monday, January 22 the firm has “Hold” rating by Needham given. On Wednesday, January 17 the stock has “Hold” rating by Wells Fargo. On Monday, January 22 the firm has “Hold” rating by Raymond James given. On Tuesday, January 23 Maxim Group downgraded the shares of JUNO in report to “Hold” rating. On Wednesday, January 17 Wedbush downgraded Juno Therapeutics, Inc. (NASDAQ:JUNO) to “Hold” rating. On Tuesday, January 23 the stock has “Market Perform” rating by Leerink Swann. On Friday, January 5 the rating was initiated by Needham with “Buy”. On Monday, January 22 Guggenheim downgraded the shares of JUNO in report to “Hold” rating. On Tuesday, December 12 the firm has “Hold” rating given by Wells Fargo. On Wednesday, January 24 Barclays Capital downgraded Juno Therapeutics, Inc. (NASDAQ:JUNO) to “Equal-Weight” rating. Listed here are Juno Therapeutics, Inc. (NASDAQ:JUNO) PTs and latest ratings.

24/01/2018 Broker: Standpoint Research Old Rating: Buy New Rating: Hold Downgrade
24/01/2018 Broker: Barclays Capital Old Rating: Overweight New Rating: Equal-Weight Downgrade
23/01/2018 Broker: Maxim Group Old Rating: Buy New Rating: Hold Downgrade
23/01/2018 Broker: Leerink Swann Old Rating: Outperform New Rating: Market Perform Old Target: $56 New Target: $87 Downgrade
23/01/2018 Broker: SunTrust Old Rating: Buy New Rating: Hold Downgrade
22/01/2018 Broker: Raymond James Rating: Hold Downgrade
22/01/2018 Broker: Needham Rating: Hold Downgrade
22/01/2018 Broker: Guggenheim Rating: Hold Downgrade
17/01/2018 Broker: Citigroup Rating: Hold New Target: $81.0 Downgrade
17/01/2018 Broker: Wedbush Rating: Hold New Target: $70.0 Downgrade

The last price was $86.96.Since May 3, 2017 it’s 0.00% down thus . JUNO underperformed by 11.55% the S&P 500.

Juno Therapeutics, Inc., a biopharmaceutical company, engages in developing cell cancer immunotherapies.The company has $10.10 billion market cap. The firm develops cell cancer immunotherapies based on its chimeric antigen receptor and T cell receptor technologies to genetically engineer T cells to recognize and kill cancer cells.Last it reported negative earnings. The Company’s CD19 product candidates include JCAR017 that is in Phase I/II trials for adults with relapsed or refractory B cell aggressive non-Hodgkin lymphoma (NHL) and pediatric patients with r/r B cell acute lymphoblastic leukemia (ALL); JCAR014, which is in Phase I/II trials to treat various B cell malignancies in patients relapsed or refractory to standard therapies; and JCAR015 that is in Phase II trials for adult patients with r/r ALL.

Juno Therapeutics, Inc. (NASDAQ:JUNO) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: